Knight Therapeutics Inc.
Transaction: 07/22/2026
OTHER
Change
0
Price
Not reported
Filing
07/29/2026
Type
OTHER
60 Degrees Pharmaceuticals, Inc.
SXTP • Biotechnology
$0.95
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$2.52M
Growth
-0.1%
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 16.9%Manageable debt level · 0.04Healthy liquidity · 2.66Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 16, 2026, 12:24 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.95
Change0.00%
Shares Out2.65M
Market Cap$2.52M
Enterprise Value$1.50M
52W Range1.05 - 8.62
Beta2.54
P/E-0.31
P/S2.27
P/B1.00
P/FCF-0.65
EV/Sales1.35
Price$0.95
Change0.00%
Shares Out2.65M
Market Cap$2.52M
Enterprise Value$1.50M
52W Range1.05 - 8.62
Beta2.54
P/E-0.31
P/S2.27
P/B1.00
P/FCF-0.65
EV/Sales1.35
EV/EBITDA-0.19
EV/FCF-0.38
Earnings Yield-321.66%
FCF Yield-154.88%
Dividend Yield0.00%
Gross Margin22.26%
Oper. Margin-7.72%
Profit Margin-7.33%
Debt/Eq0.04
Current Ratio2.66
Quick Ratio2.30
Revenue 5Y-0.12%
Volume140.75K
Avg Volume118.94K
EPS Surprise-0.52
Investment DNA
How strong this company looks for long-term investors
56
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
94/100
Why this score▼
Positive revenue growth · 16.9%Manageable debt level · 0.04Healthy liquidity · 2.66Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 2 analyst votes · 2026-09-04
75/100
Bullish
Bullish
1
Hold
1
Bearish
0
Insider Transactions
Recent executive and insider activity
DOW GEOFFREY S
Transaction: 06/12/2026
BUY
Change
+7,350
Price
$1.38
Filing
06/15/2026
Type
BUY
Francois Eric
Transaction: 05/13/2026
OTHER
Change
0
Price
Not reported
Filing
05/19/2026
Type
OTHER
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Knight Therapeutics Inc. | OTHER | 0 | Not reported | 07/22/2026 | 07/29/2026 |
| DOW GEOFFREY S | BUY | +7,350 | $1.38 | 06/12/2026 | 06/15/2026 |
| Francois Eric | OTHER | 0 | Not reported | 05/13/2026 | 05/19/2026 |
| DOW GEOFFREY S | BUY | +9,670 | $0.80 | 12/15/2025 | 12/16/2025 |
| DOW GEOFFREY S | BUY | +3,613 | $0.92 | 12/11/2025 | 12/12/2025 |
| DOW GEOFFREY S | BUY | +9,350 | $0.95 | 12/10/2025 | 12/12/2025 |
| DOW GEOFFREY S | BUY | +7,201 | $1.39 | 09/12/2025 | 09/15/2025 |
| Landon Kristen | BUY | +4,540 | Not reported | 01/17/2025 | 08/14/2025 |
| Landon Kristen | BUY | +4,167 | $6.85 | 09/26/2024 | 08/14/2025 |
| Landon Kristen | OTHER | 0 | Not reported | 02/12/2024 | 08/14/2025 |
| DOW GEOFFREY S | BUY | +4,376 | $2.99 | 06/09/2025 | 06/09/2025 |
| XU CHERYL | BUY | +3,000 | $2.87 | 06/03/2025 | 06/05/2025 |
| MILLER TYRONE | BUY | +75,000 | $1.31 | 01/02/2025 | 01/24/2025 |
| DOW GEOFFREY S | BUY | +525,000 | $1.31 | 01/02/2025 | 01/24/2025 |
| MILLER TYRONE | BUY | +11,626 | Not reported | 01/17/2025 | 01/21/2025 |
| DOW GEOFFREY S | BUY | +14,394 | Not reported | 01/17/2025 | 01/21/2025 |
| XU CHERYL | BUY | +2,000 | $1.45 | 12/16/2024 | 12/18/2024 |
| XU CHERYL | BUY | +1,500 | $1.60 | 12/13/2024 | 12/18/2024 |
| XU CHERYL | BUY | +2,500 | $1.85 | 12/12/2024 | 12/18/2024 |
| DOW GEOFFREY S | BUY | +35,823 | $1.27 | 12/09/2024 | 12/09/2024 |